Cargando…
Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890990/ https://www.ncbi.nlm.nih.gov/pubmed/33596825 http://dx.doi.org/10.1186/s12879-021-05880-8 |
| _version_ | 1783652610852519936 |
|---|---|
| author | Xu, Ling Peng, Wenxiu Song, Xiaojing Li, Yanling Han, Yang Zhu, Ting Fu, Qiang Du, Xiaoli Cao, Wei Li, Taisheng |
| author_facet | Xu, Ling Peng, Wenxiu Song, Xiaojing Li, Yanling Han, Yang Zhu, Ting Fu, Qiang Du, Xiaoli Cao, Wei Li, Taisheng |
| author_sort | Xu, Ling |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7890990 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78909902021-02-22 Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study Xu, Ling Peng, Wenxiu Song, Xiaojing Li, Yanling Han, Yang Zhu, Ting Fu, Qiang Du, Xiaoli Cao, Wei Li, Taisheng BMC Infect Dis Correction BioMed Central 2021-02-17 /pmc/articles/PMC7890990/ /pubmed/33596825 http://dx.doi.org/10.1186/s12879-021-05880-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Xu, Ling Peng, Wenxiu Song, Xiaojing Li, Yanling Han, Yang Zhu, Ting Fu, Qiang Du, Xiaoli Cao, Wei Li, Taisheng Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study |
| title | Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study |
| title_full | Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study |
| title_fullStr | Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study |
| title_full_unstemmed | Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study |
| title_short | Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study |
| title_sort | correction to: pharmacodynamics of efavirenz 400 mg in treatment-naïve chinese hiv-infected patients in a prospective cohort study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890990/ https://www.ncbi.nlm.nih.gov/pubmed/33596825 http://dx.doi.org/10.1186/s12879-021-05880-8 |
| work_keys_str_mv | AT xuling correctiontopharmacodynamicsofefavirenz400mgintreatmentnaivechinesehivinfectedpatientsinaprospectivecohortstudy AT pengwenxiu correctiontopharmacodynamicsofefavirenz400mgintreatmentnaivechinesehivinfectedpatientsinaprospectivecohortstudy AT songxiaojing correctiontopharmacodynamicsofefavirenz400mgintreatmentnaivechinesehivinfectedpatientsinaprospectivecohortstudy AT liyanling correctiontopharmacodynamicsofefavirenz400mgintreatmentnaivechinesehivinfectedpatientsinaprospectivecohortstudy AT hanyang correctiontopharmacodynamicsofefavirenz400mgintreatmentnaivechinesehivinfectedpatientsinaprospectivecohortstudy AT zhuting correctiontopharmacodynamicsofefavirenz400mgintreatmentnaivechinesehivinfectedpatientsinaprospectivecohortstudy AT fuqiang correctiontopharmacodynamicsofefavirenz400mgintreatmentnaivechinesehivinfectedpatientsinaprospectivecohortstudy AT duxiaoli correctiontopharmacodynamicsofefavirenz400mgintreatmentnaivechinesehivinfectedpatientsinaprospectivecohortstudy AT caowei correctiontopharmacodynamicsofefavirenz400mgintreatmentnaivechinesehivinfectedpatientsinaprospectivecohortstudy AT litaisheng correctiontopharmacodynamicsofefavirenz400mgintreatmentnaivechinesehivinfectedpatientsinaprospectivecohortstudy |